X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (581) 581
campath-1h (514) 514
alemtuzumab (470) 470
male (322) 322
antibodies, monoclonal, humanized (309) 309
female (289) 289
index medicus (287) 287
middle aged (281) 281
antibodies, monoclonal - therapeutic use (259) 259
hematology (243) 243
transplantation (241) 241
adult (239) 239
antibodies, neoplasm - therapeutic use (211) 211
oncology (182) 182
aged (176) 176
therapy (158) 158
treatment outcome (157) 157
antineoplastic agents - therapeutic use (139) 139
immunology (138) 138
alemtuzumab campath-1h (130) 130
surgery (122) 122
leukemia, lymphocytic, chronic, b-cell - drug therapy (112) 112
fludarabine (105) 105
chronic lymphocytic-leukemia (103) 103
immunosuppressive agents - therapeutic use (100) 100
rituximab (100) 100
cd52 antigen (90) 90
antibodies, monoclonal - adverse effects (89) 89
monoclonal antibodies (87) 87
adolescent (83) 83
antibodies, neoplasm - adverse effects (83) 83
antibodies, monoclonal - administration & dosage (81) 81
antibodies, neoplasm - administration & dosage (76) 76
chronic lymphocytic leukemia (69) 69
immunosuppression (68) 68
immunotherapy (68) 68
monoclonal-antibody (64) 64
antibodies, monoclonal, humanized - therapeutic use (63) 63
cd52 (63) 63
retrospective studies (60) 60
care and treatment (58) 58
renal-transplantation (57) 57
antineoplastic combined chemotherapy protocols - therapeutic use (56) 56
animals (55) 55
kidney transplantation (53) 53
recipients (53) 53
stem-cell transplantation (52) 52
follow-up studies (51) 51
t cells (51) 51
antibody (50) 50
health aspects (50) 50
transplantation, homologous (50) 50
cll (49) 49
risk factors (49) 49
vidarabine - analogs & derivatives (49) 49
antigens, cd - immunology (47) 47
graft rejection - prevention & control (47) 47
time factors (47) 47
child (46) 46
kidney-transplantation (46) 46
leukemia (46) 46
monoclonal antibody (46) 46
disease (45) 45
leukemia, lymphocytic, chronic, b-cell - therapy (45) 45
phase-ii trial (45) 45
recurrence (45) 45
aged, 80 and over (44) 44
remission induction (44) 44
young adult (44) 44
antibodies, monoclonal - pharmacology (43) 43
antibodies, neoplasm - pharmacology (43) 43
chemotherapy (43) 43
t-cells (43) 43
campath‐1h (42) 42
induction (42) 42
tacrolimus (42) 42
antineoplastic agents - adverse effects (41) 41
bone-marrow-transplantation (41) 41
kidney transplantation - immunology (41) 41
lymphocytes (41) 41
tolerance (41) 41
clinical trials as topic (40) 40
survival analysis (40) 40
antigens, neoplasm - immunology (39) 39
drug therapy (39) 39
glycoproteins - immunology (39) 39
antibodies (38) 38
lymphocyte depletion (38) 38
lymphoma (38) 38
multiple sclerosis (38) 38
versus-host-disease (38) 38
cancer (37) 37
flow cytometry (37) 37
non-hodgkins-lymphoma (37) 37
graft rejection - immunology (36) 36
research (36) 36
drug therapy, combination (35) 35
article (34) 34
expression (34) 34
kidneys (34) 34
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (682) 682
German (8) 8
Russian (2) 2
French (1) 1
Hungarian (1) 1
Japanese (1) 1
Korean (1) 1
Polish (1) 1
Portuguese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NEUROLOGY, ISSN 0028-3878, 04/2012, Volume 78, Issue 14, pp. 1069 - 1078
Objective: To report the long-term safety and efficacy results from CAMMS223 comparing alemtuzumab with interferon beta-1a in early, active relapsing-remitting... 
CAMPATH-1H | THERAPEUTIC LYMPHOCYTE DEPLETION | MULTIPLE-SCLEROSIS | CLINICAL NEUROLOGY
Journal Article
Lancet, The, ISSN 0140-6736, 11/2012, Volume 380, Issue 9856, pp. 1829 - 1839
Journal Article
JOURNAL OF NEUROLOGY, ISSN 0340-5354, 01/2006, Volume 253, Issue 1, pp. 98 - 108
From 1991-2002, we treated 58 patients with multiple sclerosis (MS) using the humanised monoclonal antibody, Campath-1H, which causes prolonged T lymphocyte... 
RHEUMATOID-ARTHRITIS | INTERFERON TREATMENT | CONTROLLED-TRIAL | THYROID-FUNCTION | multiple sclerosis | cerebral atrophy | PROGRESSIVE MS | Campath-1H | CLINICAL-COURSE | CLINICAL NEUROLOGY | AUTOIMMUNE-DISEASES | NITRIC-OXIDE | MONOCLONAL-ANTIBODY THERAPY | ANTITHYROID ANTIBODIES
Journal Article
Transplantation Proceedings, ISSN 0041-1345, 12/2018, Volume 50, Issue 10, pp. 3739 - 3747
Background and objectives: Heart and lung transplantation is a high-risk procedure, requiring intensive immunosuppressive therapy for preventing organ... 
SURGERY | CAMPATH-1H | CD52 | IMPACT | IMMUNOSUPPRESSION | TIME | OUTCOMES | IMMUNOLOGY | TACROLIMUS | BASILIXIMAB INDUCTION | TRANSPLANTATION
Journal Article
American Journal of Transplantation, ISSN 1600-6135, 08/2009, Volume 9, Issue 8, pp. 1835 - 1845
Alemtuzumab is a monoclonal antibody that depletes T and B cells and is used as induction therapy for renal transplant recipients. Without long-term... 
BAFF | Campath-1H | Alemtuzumab | sirolimus | renal transplant | Campath‐1H | Renal transplant | Sirolimus | B-LYMPHOCYTE STIMULATOR | SURGERY | CAMPATH-1H INDUCTION | SYSTEMIC-LUPUS-ERYTHEMATOSUS | PRIMARY SJOGRENS-SYNDROME | TRANSPLANTATION | OVEREXPRESSION | CELL ACTIVATING FACTOR | REGULATORY T-CELLS | ALLOGRAFT RECIPIENTS | IMMUNOSUPPRESSIVE DRUGS | APRIL | Antibodies, Neoplasm - therapeutic use | Kidney Transplantation - pathology | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Case-Control Studies | Antigens, CD - metabolism | Transmembrane Activator and CAML Interactor Protein - metabolism | Young Adult | Antibodies, Monoclonal, Humanized | Antibodies, Neoplasm - pharmacology | T-Lymphocytes - drug effects | Adult | Female | B-Lymphocytes - pathology | T-Lymphocytes - pathology | Graft Rejection - pathology | Tumor Necrosis Factor Ligand Superfamily Member 13 - blood | Antibodies, Monoclonal - pharmacology | Graft Rejection - prevention & control | Lectins, C-Type | Antigens, Differentiation, T-Lymphocyte - metabolism | B-Lymphocytes - drug effects | B-Cell Maturation Antigen - metabolism | Interleukin-2 Receptor alpha Subunit - metabolism | Adolescent | Aged | B-Cell Activating Factor - blood | Care and treatment | Messenger RNA | Kidneys | Lymphocytes | Analysis | Organ transplant recipients | Transplantation | Public health
Journal Article
Transplantation Proceedings, ISSN 0041-1345, 12/2018, Volume 50, Issue 10, pp. 3723 - 3731
Heart and lung transplantation is a high-risk procedure requiring intensive immunosuppressive therapy for preventing organ rejection. Alemtuzumab, a... 
SURGERY | CAMPATH-1H | CD52 | PHARMACODYNAMICS | TIME | IMMUNOLOGY | BASILIXIMAB INDUCTION | TRANSPLANTATION | IMPACT | PHARMACOKINETICS | RECEIVING ALEMTUZUMAB | OUTCOMES | TACROLIMUS
Journal Article
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2005, Volume 23, Issue 13, pp. 2971 - 2979
Purpose To test whether eradication of minimal residual disease (MRD) in B-cell chronic lymphocytic leukemia (CLL) by alemtuzumab is associated with a... 
PROGNOSTIC FACTORS | CAMPATH-1H | CD52 | CLL | ONCOLOGY | TERM-FOLLOW-UP | MONOCLONAL-ANTIBODY |